Clinical Development - SNS-101 Phase 1/2 dose expansion clinical data is expected in the first half of 2025[1] - The company plans to re-engage with the FDA regarding the dose optimization strategy for SNS-101 following additional data from the ongoing clinical trial[5] - Approximately half of the dose expansion study for SNS-101 has been enrolled, targeting patients with primary and acquired resistance to PD-1 inhibitors[4] Financial Performance - Cash, cash equivalents, and marketable securities were $47.0 million as of September 30, 2024, expected to fund operations into the second quarter of 2026[7] - The net loss for Q3 2024 was $7.3 million, compared to a net loss of $7.1 million in Q3 2023[9] - Total operating expenses for Q3 2024 were $7.8 million, slightly higher than $7.7 million in Q3 2023[11] Expenses - Research and Development (R&D) expenses increased to $4.6 million for Q3 2024, up from $3.8 million in Q3 2023, primarily due to higher clinical trial costs[8] - General and Administrative (G&A) expenses decreased to $3.2 million for Q3 2024, down from $3.9 million in Q3 2023, due to lower insurance premiums and outside services[9] Workforce Reduction - The company has reduced its workforce by approximately 46% to focus resources on advancing the clinical development of SNS-101[6] Asset Management - Total assets as of September 30, 2024, were $53.3 million, down from $74.4 million as of December 31, 2023[12]
sensei(SNSE) - 2024 Q3 - Quarterly Results